199 related articles for article (PubMed ID: 37170680)
1. Physiologically based pharmacokinetic modeling of levetiracetam to predict the exposure in hepatic and renal impairment and elderly populations.
Shen C; Shao W; Wang W; Sun H; Wang X; Geng K; Wang X; Xie H
CPT Pharmacometrics Syst Pharmacol; 2023 Jul; 12(7):1001-1015. PubMed ID: 37170680
[TBL] [Abstract][Full Text] [Related]
2. Physiologically based pharmacokinetic modeling of candesartan to predict the exposure in hepatic and renal impairment and elderly populations.
Guo L; Zhu X; Zhang L; Xu Y
Ther Adv Drug Saf; 2023; 14():20420986231220222. PubMed ID: 38157240
[TBL] [Abstract][Full Text] [Related]
3. Physiologically based pharmacokinetic modeling of apixaban to predict exposure in populations with hepatic and renal impairment and elderly populations.
Xu Y; Zhang L; Dou X; Dong Y; Guo X
Eur J Clin Pharmacol; 2024 Feb; 80(2):261-271. PubMed ID: 38099940
[TBL] [Abstract][Full Text] [Related]
4. Development and Validation of Physiologically Based Pharmacokinetic Model of Levetiracetam to Predict Exposure and Dose Optimization in Pediatrics.
Shao W; Shen C; Wang W; Sun H; Wang X; Geng K; Wang X; Xie H
J Pharm Sci; 2023 Oct; 112(10):2667-2675. PubMed ID: 37023853
[TBL] [Abstract][Full Text] [Related]
5. Physiologically Based Pharmacokinetic Modeling of Lacosamide in Patients With Hepatic and Renal Impairment and Pediatric Populations to Support Pediatric Dosing Optimization.
Zhu X; Guo L; Zhang L; Xu Y
Clin Ther; 2024 Mar; 46(3):258-266. PubMed ID: 38369451
[TBL] [Abstract][Full Text] [Related]
6. Development of a physiologically based pharmacokinetic model for levetiracetam in patients with renal impairment to guide dose adjustment based on steady-state peak/trough concentrations.
Wang R; Wang T; Han X; Chen M; Li S
Xenobiotica; 2024 Mar; 54(3):116-123. PubMed ID: 38344757
[TBL] [Abstract][Full Text] [Related]
7. Physiologically Based Pharmacokinetic Modelling and Prediction of Metformin Pharmacokinetics in Renal/Hepatic-Impaired Young Adults and Elderly Populations.
Rhee SJ; Chung H; Yi S; Yu KS; Chung JY
Eur J Drug Metab Pharmacokinet; 2017 Dec; 42(6):973-980. PubMed ID: 28536774
[TBL] [Abstract][Full Text] [Related]
8. Physiologically-based pharmacokinetic modeling for optimal dosage prediction of olaparib when co-administered with CYP3A4 modulators and in patients with hepatic/renal impairment.
Gao D; Wang G; Wu H; Ren J
Sci Rep; 2023 Sep; 13(1):16027. PubMed ID: 37749178
[TBL] [Abstract][Full Text] [Related]
9. Application of physiologically based pharmacokinetic modeling to predict the pharmacokinetics of telavancin in obesity with renal impairment.
Wu W; Ke M; Ye L; Lin C
Eur J Clin Pharmacol; 2021 Jul; 77(7):989-998. PubMed ID: 33447912
[TBL] [Abstract][Full Text] [Related]
10. Physiologically-based pharmacokinetic modeling for single and multiple dosing regimens of ceftriaxone in healthy and chronic kidney disease populations: a tool for model-informed precision dosing.
Alasmari F; Alasmari MS; Muwainea HM; Alomar HA; Alasmari AF; Alsanea S; Alshamsan A; Rasool MF; Alqahtani F
Front Pharmacol; 2023; 14():1200828. PubMed ID: 37547336
[No Abstract] [Full Text] [Related]
11. Asenapine pharmacokinetics in hepatic and renal impairment.
Peeters P; Bockbrader H; Spaans E; Dogterom P; Lasseter K; Marbury T; Gibson GL; de Greef R
Clin Pharmacokinet; 2011 Jul; 50(7):471-81. PubMed ID: 21651314
[TBL] [Abstract][Full Text] [Related]
12. Application of Physiologically Based Pharmacokinetic Modeling to Predict Drug Exposure and Support Dosing Recommendations for Potential Drug-Drug Interactions or in Special Populations: An Example Using Tofacitinib.
Tse S; Dowty ME; Menon S; Gupta P; Krishnaswami S
J Clin Pharmacol; 2020 Dec; 60(12):1617-1628. PubMed ID: 32592424
[TBL] [Abstract][Full Text] [Related]
13. Simulation of the pharmacokinetics of bisoprolol in healthy adults and patients with impaired renal function using whole-body physiologically based pharmacokinetic modeling.
Li GF; Wang K; Chen R; Zhao HR; Yang J; Zheng QS
Acta Pharmacol Sin; 2012 Nov; 33(11):1359-71. PubMed ID: 23085739
[TBL] [Abstract][Full Text] [Related]
14. Optimizing the Clinical Use of Carvedilol in Liver Cirrhosis Using a Physiologically Based Pharmacokinetic Modeling Approach.
Rasool MF; Khalil F; Läer S
Eur J Drug Metab Pharmacokinet; 2017 Jun; 42(3):383-396. PubMed ID: 27313074
[TBL] [Abstract][Full Text] [Related]
15. Physiologically-based pharmacokinetic model for alectinib, ruxolitinib, and panobinostat in the presence of cancer, renal impairment, and hepatic impairment.
Alsmadi MM; Al-Daoud NM; Jaradat MM; Alzughoul SB; Abu Kwiak AD; Abu Laila SS; Abu Shameh AJ; Alhazabreh MK; Jaber SA; Abu Kassab HT
Biopharm Drug Dispos; 2021 Jun; 42(6):263-284. PubMed ID: 33904202
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic Drug Monitoring of Levetiracetam in Select Populations.
Jarvie D; Mahmoud SH
J Pharm Pharm Sci; 2018; 21(1s):149s-176s. PubMed ID: 30096051
[TBL] [Abstract][Full Text] [Related]
17. Physiologically based pharmacokinetic modelling to predict exposure differences in healthy volunteers and subjects with renal impairment: Ceftazidime case study.
Zhou L; Tong X; Sharma P; Xu H; Al-Huniti N; Zhou D
Basic Clin Pharmacol Toxicol; 2019 Aug; 125(2):100-107. PubMed ID: 30739396
[TBL] [Abstract][Full Text] [Related]
18. Prediction of pharmacokinetics and pharmacodynamics of trelagliptin and omarigliptin in healthy humans and in patients with renal impairment using physiologically based pharmacokinetic combined DPP-4 occupancy modeling.
Wu C; Liu H; Yu S; Ren C; Zhang J; Wang G; Li B; Liu Y
Biomed Pharmacother; 2022 Sep; 153():113509. PubMed ID: 36076596
[TBL] [Abstract][Full Text] [Related]
19. Applications of Physiologically Based Pharmacokinetic Modeling of Rivaroxaban-Renal and Hepatic Impairment and Drug-Drug Interaction Potential.
Willmann S; Coboeken K; Kapsa S; Thelen K; Mundhenke M; Fischer K; Hügl B; Mück W
J Clin Pharmacol; 2021 May; 61(5):656-665. PubMed ID: 33205449
[TBL] [Abstract][Full Text] [Related]
20. Physiologically based pharmacokinetic modelling of treprostinil after intravenous injection and extended-release oral tablet administration in healthy volunteers: An extrapolation to other patient populations including patients with hepatic impairment.
Wu X; Zhang X; Xu R; Shaik IH; Venkataramanan R
Br J Clin Pharmacol; 2022 Feb; 88(2):587-599. PubMed ID: 34190364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
